Loading...
•
Dec 31, 2022
Rhythm Pharmaceuticals Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Rhythm Pharmaceuticals reported a strong 2022, highlighted by the successful U.S. launch of IMCIVREE for Bardet-Biedl syndrome (BBS) following FDA approval in June and its expansion into eight international markets. The company also initiated a pivotal Phase 3 trial for setmelanotide in hypothalamic obesity and acquired Xinvento B.V. to broaden its pipeline into congenital hyperinsulinism (CHI).
IMCIVREE U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval
IMCIVREE now available in eight ex-U.S. markets; first commercial sales for BBS expected in Germany in 2Q 2023
Pivotal Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity initiated
Acquired Xinvento B.V., a rare disease company in preclinical development for congenital hyperinsulinism
Forward Guidance
Rhythm anticipates approximately $200 million to $220 million in Non-GAAP Operating Expenses for the year ending December 31, 2023, comprised of $120 million to $130 million from R&D expenses and $80 million to $90 million from S,G&A expenses. The company expects its existing cash, cash equivalents and short-term investments as of December 31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...